Literature DB >> 10155310

Relationships between sponsors and investigators in pharmacoeconomic and clinical research.

K A Schulman1, L E Rubenstein, H A Glick, J M Eisenberg.   

Abstract

Potential conflict between the goals of the investigators and the sponsors of pharmacoeconomic and clinical research has been well documented. Although there have been efforts to formalise relationships between sponsors and investigators in some areas of clinical research, no set of guidelines or standardised contract to govern pharmacoeconomic research relationships is currently in use. In this paper, we discuss a number of provisions that should be included in a sponsored research agreement to define the responsibilities and clarify the rights of the parties in the collaborative research relationship. We also present an example of a sponsored research agreement that we have designed as a model formal contract between sponsors and investigators. The most salient areas in the research agreement include: publication, specification of analysis, data access/ownership, confidentiality, termination and payment to investigators. While this paper focuses on pharmacoeconomic research, many of the principles have relevance to a broader range of research relationships and to other clinical economics and clinical trials research.

Mesh:

Year:  1995        PMID: 10155310     DOI: 10.2165/00019053-199507030-00004

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN: 1170-7690            Impact factor:   4.981


  25 in total

1.  Fraud and misconduct in clinical research: is it prejudicial to patient safety?

Authors:  F Wells
Journal:  Adverse Drug React Toxicol Rev       Date:  1992

2.  Adventurism in biomedical science: Washington University-Monsanto program in biotechnology.

Authors:  J I Gordon
Journal:  Pharos Alpha Omega Alpha Honor Med Soc       Date:  1992

3.  The existence of publication bias and risk factors for its occurrence.

Authors:  K Dickersin
Journal:  JAMA       Date:  1990-03-09       Impact factor: 56.272

4.  Uniform requirements for manuscripts submitted to biomedical journals. International Committee of Medical Journal Editors.

Authors: 
Journal:  JAMA       Date:  1993-05-05       Impact factor: 56.272

5.  Physicians and the pharmaceutical industry. American College of Physicians.

Authors: 
Journal:  Ann Intern Med       Date:  1990-04-15       Impact factor: 25.391

Review 6.  Industry reimbursement for entering patients into clinical trials: legal and ethical issues.

Authors:  D S Shimm; R G Spece
Journal:  Ann Intern Med       Date:  1991-07-15       Impact factor: 25.391

7.  Misrepresentation and responsibility in medical research.

Authors:  R L Engler; J W Covell; P J Friedman; P S Kitcher; R M Peters
Journal:  N Engl J Med       Date:  1987-11-26       Impact factor: 91.245

8.  Dealing with conflicts of interest.

Authors:  A S Relman
Journal:  N Engl J Med       Date:  1984-05-03       Impact factor: 91.245

9.  Ethics, economics, and the publication policies of major medical journals.

Authors:  K Schulman; D P Sulmasy; D Roney
Journal:  JAMA       Date:  1994-07-13       Impact factor: 56.272

10.  Inappropriate publication of trial results and potential for allegations of illegal share dealing.

Authors:  D S Freestone; H Mitchell
Journal:  BMJ       Date:  1993-04-24
View more
  8 in total

Review 1.  Conflict of interest in industry-sponsored economic evaluations: real or imagined?

Authors:  M Barbieri; M F Drummond
Journal:  Curr Oncol Rep       Date:  2001-09       Impact factor: 5.075

2.  A reappraisal of economic evaluation of pharmaceuticals. Science or marketing?

Authors:  M F Drummond
Journal:  Pharmacoeconomics       Date:  1998-07       Impact factor: 4.981

Review 3.  Why training is the key to successful guideline implementation.

Authors:  A D Paltiel; P J Neumann
Journal:  Pharmacoeconomics       Date:  1997-09       Impact factor: 4.981

4.  A strategy for collecting pharmacoeconomic data during phase II/III clinical trials.

Authors:  J Mauskopf; K Schulman; L Bell; H Glick
Journal:  Pharmacoeconomics       Date:  1996-03       Impact factor: 4.981

5.  Cost effectiveness of recombinant human insulin-like growth factor I therapy in patients with ALS.

Authors:  S J Ackerman; E M Sullivan; K M Beusterien; H M Natter; D F Gelinas; D L Patrick
Journal:  Pharmacoeconomics       Date:  1999-02       Impact factor: 4.981

6.  Comparison of the costs of nonoperative care to minimally invasive surgery for sacroiliac joint disruption and degenerative sacroiliitis in a United States commercial payer population: potential economic implications of a new minimally invasive technology.

Authors:  Stacey J Ackerman; David W Polly; Tyler Knight; Karen Schneider; Tim Holt; John Cummings
Journal:  Clinicoecon Outcomes Res       Date:  2014-05-24

7.  Management of sacroiliac joint disruption and degenerative sacroiliitis with nonoperative care is medical resource-intensive and costly in a United States commercial payer population.

Authors:  Stacey J Ackerman; David W Polly; Tyler Knight; Tim Holt; John Cummings
Journal:  Clinicoecon Outcomes Res       Date:  2014-02-11

8.  Comparison of the costs of nonoperative care to minimally invasive surgery for sacroiliac joint disruption and degenerative sacroiliitis in a United States Medicare population: potential economic implications of a new minimally-invasive technology.

Authors:  Stacey J Ackerman; David W Polly; Tyler Knight; Karen Schneider; Tim Holt; John Cummings
Journal:  Clinicoecon Outcomes Res       Date:  2013-11-20
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.